ALXN News and Press, Alexion Pharmaceuticals Inc. From 07/12/20

Longtime investors have seen some crazy things transpire over the years, but nothing could have prepared them for the volatility caused by the coronavirus disease 2019 (COVID-19) pandemic. With the first-half of 2020 now in the books, we've witnessed the benchmark S&P 500 lose more than a ...

Quick Take Annexon ( ANNX ) has filed to raise $100 million in an IPO of its common stock, according to an S-1 registration statement. The company is a clinical stage biopharma developing antibodies for treating autoimmune and neurodegenerative diseases. ANNX is targeting a number of s...

Introduction I find it very interesting that Alexion Pharmaceuticals Inc. ( ALXN ), after going public in 2001, did not generate their first profit until December 2008. As we all know, this was in the throes of what is now known as the Great Recession of 2008. Moreover, Alexion’s ad...

In early April, I published a list of Magic Formula stocks that had a market cap of $2.5bn or greater. In this update, I intend to look into how certain companies or segments of that selection have performed and how the Magic Formula selection has changed during the stock market recovery. ...

Alexion Pharmaceuticals (NASDAQ: ALXN) is reaching into its coffers to settle charges leveled against it by the Securities and Exchange Commission. The company will hand over a total of roughly $21.5 million in disgorgement, civil penalties, and pre-judgment interest to the regulator. The S...

Alexion Pharmaceuticals (NASDAQ: ALXN ) has completed its acquisition of Portola Pharmaceuticals (NASDAQ: PTLA ), through a tender offer and merger with its subsidiary, Odyssey Merger Sub Inc. (“Buyer”). More news on: Alexion Pharmaceuticals, Inc., Portola Pharmaceutic...

Reacting to fiscal Q4 earnings - and some key competitor updates - Nomura Instinet is sticking with a recently initiated Buy rating on "catalyst-rich" Immunovant (NASDAQ: IMVT ) and now sees the company with a long cash runway. More news on: Immunovant, Inc., Horizon Therapeutics Public ...

Alexion Pharma Receives European Approval for Ultomiris Alexion Pharmaceuticals ( ALXN ) announced that its lead drug candidate Ultomiris has been approved by the European Commission. Ultomiris may now be used for treating adults and children with atypical hemolytic uremic syndrome in Eu...

– ULTOMIRIS is the first and only long-acting C5 inhibitor for aHUS, administered every other month, reducing the treatment burden for adults and children – – ULTOMIRIS has the potential to become the new standard of care in Europe for the treatment of aHUS ...

If 2020 has taught Wall Street and investors anything -- aside from the fact that stock market crashes are an inevitable part of the investing process -- it's that staying the course with great companies is a smart move. Uncertainty tied to the unprecedented coronavirus disease 2019 (COVID-19...